Garry Schwartz - Concepedia

Author

Garry Schwartz

The University of Texas Health Science Center at San Antonio

Also Known As

G Schwartz, G. H. Schwartz, G. Schwartz, G.H. Schwartz, Garry H Schwartz, Garry H. Schwartz, Garry Schwartz, Lee, Carrie, Weck, Karen E.

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Brooke Army Medical Center Wilford Hall Ambulatory Surgical Center Levine Cancer Institute University of North Carolina at Chapel Hill

About

Garry Schwartz is an author at The University of Texas Health Science Center at San Antonio specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.2K
2	Health Sciences	1	1	578
3	Natural Sciences	1	1	366
4	Biochemistry	1	1	366
5	Chemical Biology	1	1	366

Garry Schwartz

Publications

Citations

H-Index

Page 1

	Year	Citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Anthony W. Tolcher, Stanton L. Gerson, Christiane Geyer, British Journal of Cancer Dna DamageMolecular BiologyPathologyChemical BiologyMarked Inactivation	2003	366
Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer Eric K. Rowinsky, Garry Schwartz, Jared Gollob, Journal of Clinical Oncology	2004	323
Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study Anthony W. Tolcher, Leonel Ochoa, Lisa A. Hammond, Journal of Clinical Oncology	2003	204
A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Anthony W. Tolcher, Kim Chi, John G. Kuhn, Clinical Cancer Research	2005	164
Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Clinical Cancer Research	2008	156
A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies Eric K. Rowinsky, Jinee Rizzo, Leonel Ochoa, Journal of Clinical Oncology	2002	132
A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Anthony W. Tolcher, John G. Kuhn, Garry Schwartz, Clinical Cancer Research	2004	81
Incorporating Bevacizumab and Erlotinib in the Combined-Modality Treatment of Stage III Non–Small-Cell Lung Cancer: Results of a Phase I/II Trial Mark A. Socinski, Thomas E. Stinchcombe, Dominic T. Moore, Journal of Clinical Oncology	2012	78
A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties Samira Syed, Chris H. Takimoto, Manuel Hidalgo, Clinical Cancer Research	2004	64

Page 1